Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging.
Identifieur interne : 000562 ( Main/Exploration ); précédent : 000561; suivant : 000563Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging.
Auteurs : Ahmed S. Abdelhamid [Égypte] ; Maged W. Helmy [Égypte] ; Shaker M. Ebrahim [Égypte] ; Mohammed Bahey-El-Din [Égypte] ; Dina G. Zayed [Égypte] ; Esmat A. Zein El Dein [Égypte] ; Sanaa A. El-Gizawy [Égypte] ; Ahmed O. Elzoghby [Égypte, États-Unis]Source :
- Nanomedicine (London, England) [ 1748-6963 ] ; 2018.
Abstract
Aim: Nanotheranostics consisting of highly-fluorescent quantum dots coupled with gelatin/chondroitin layer-by-layer assembled nanocapsules were developed. Materials & methods: The hydrophobic drugs celecoxib (CXB) and rapamycin (RAP) were co-loaded into the oily core of nanocapsules (NCs) to enable synergistic growth inhibition of breast cancer cells. To overcome the nonspecific binding of actively targeted CS-NCs with normal cells, a matrix metalloproteinase (MMP-2)-degradable cationic gelatin layer was electrostatically deposited onto the surface of the negatively-charged CS-NCs. Results: The prepared nanocarriers displayed strong fluorescence which enabled tracing their internalization into cancer cells. An enhanced cytotoxicity of the NCs against breast cancer cells was demonstrated. In vivo, the nanoplatforms displayed superior antitumor efficacy as well as nonimmunogenic response. Conclusion: Therefore, these multifunctional nanoplatforms could be used as potential cancer theranostics.
DOI: 10.2217/nnm-2018-0028
PubMed: 30073915
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging.</title><author><name sortKey="Abdelhamid, Ahmed S" sort="Abdelhamid, Ahmed S" uniqKey="Abdelhamid A" first="Ahmed S" last="Abdelhamid">Ahmed S. Abdelhamid</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta</wicri:regionArea><wicri:noRegion>Tanta</wicri:noRegion></affiliation></author><author><name sortKey="Helmy, Maged W" sort="Helmy, Maged W" uniqKey="Helmy M" first="Maged W" last="Helmy">Maged W. Helmy</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, El Bahira, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, El Bahira</wicri:regionArea><wicri:noRegion>El Bahira</wicri:noRegion></affiliation></author><author><name sortKey="Ebrahim, Shaker M" sort="Ebrahim, Shaker M" uniqKey="Ebrahim S" first="Shaker M" last="Ebrahim">Shaker M. Ebrahim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Materials Science, Institute of Graduate Studies & Research, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Materials Science, Institute of Graduate Studies & Research, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation></author><author><name sortKey="Bahey El Din, Mohammed" sort="Bahey El Din, Mohammed" uniqKey="Bahey El Din M" first="Mohammed" last="Bahey-El-Din">Mohammed Bahey-El-Din</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology & Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Microbiology & Immunology, Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation></author><author><name sortKey="Zayed, Dina G" sort="Zayed, Dina G" uniqKey="Zayed D" first="Dina G" last="Zayed">Dina G. Zayed</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation></author><author><name sortKey="Zein El Dein, Esmat A" sort="Zein El Dein, Esmat A" uniqKey="Zein El Dein E" first="Esmat A" last="Zein El Dein">Esmat A. Zein El Dein</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta</wicri:regionArea><wicri:noRegion>Tanta</wicri:noRegion></affiliation></author><author><name sortKey="El Gizawy, Sanaa A" sort="El Gizawy, Sanaa A" uniqKey="El Gizawy S" first="Sanaa A" last="El-Gizawy">Sanaa A. El-Gizawy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta</wicri:regionArea><wicri:noRegion>Tanta</wicri:noRegion></affiliation></author><author><name sortKey="Elzoghby, Ahmed O" sort="Elzoghby, Ahmed O" uniqKey="Elzoghby A" first="Ahmed O" last="Elzoghby">Ahmed O. Elzoghby</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="2"><nlm:affiliation>Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:30073915</idno><idno type="pmid">30073915</idno><idno type="doi">10.2217/nnm-2018-0028</idno><idno type="wicri:Area/Main/Corpus">000490</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000490</idno><idno type="wicri:Area/Main/Curation">000490</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000490</idno><idno type="wicri:Area/Main/Exploration">000490</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging.</title><author><name sortKey="Abdelhamid, Ahmed S" sort="Abdelhamid, Ahmed S" uniqKey="Abdelhamid A" first="Ahmed S" last="Abdelhamid">Ahmed S. Abdelhamid</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta</wicri:regionArea><wicri:noRegion>Tanta</wicri:noRegion></affiliation></author><author><name sortKey="Helmy, Maged W" sort="Helmy, Maged W" uniqKey="Helmy M" first="Maged W" last="Helmy">Maged W. Helmy</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, El Bahira, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, El Bahira</wicri:regionArea><wicri:noRegion>El Bahira</wicri:noRegion></affiliation></author><author><name sortKey="Ebrahim, Shaker M" sort="Ebrahim, Shaker M" uniqKey="Ebrahim S" first="Shaker M" last="Ebrahim">Shaker M. Ebrahim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Materials Science, Institute of Graduate Studies & Research, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Materials Science, Institute of Graduate Studies & Research, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation></author><author><name sortKey="Bahey El Din, Mohammed" sort="Bahey El Din, Mohammed" uniqKey="Bahey El Din M" first="Mohammed" last="Bahey-El-Din">Mohammed Bahey-El-Din</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology & Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Microbiology & Immunology, Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation></author><author><name sortKey="Zayed, Dina G" sort="Zayed, Dina G" uniqKey="Zayed D" first="Dina G" last="Zayed">Dina G. Zayed</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation></author><author><name sortKey="Zein El Dein, Esmat A" sort="Zein El Dein, Esmat A" uniqKey="Zein El Dein E" first="Esmat A" last="Zein El Dein">Esmat A. Zein El Dein</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta</wicri:regionArea><wicri:noRegion>Tanta</wicri:noRegion></affiliation></author><author><name sortKey="El Gizawy, Sanaa A" sort="El Gizawy, Sanaa A" uniqKey="El Gizawy S" first="Sanaa A" last="El-Gizawy">Sanaa A. El-Gizawy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta</wicri:regionArea><wicri:noRegion>Tanta</wicri:noRegion></affiliation></author><author><name sortKey="Elzoghby, Ahmed O" sort="Elzoghby, Ahmed O" uniqKey="Elzoghby A" first="Ahmed O" last="Elzoghby">Ahmed O. Elzoghby</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</nlm:affiliation><country xml:lang="fr">Égypte</country><wicri:regionArea>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria</wicri:regionArea><wicri:noRegion>Alexandria</wicri:noRegion></affiliation><affiliation wicri:level="2"><nlm:affiliation>Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><nlm:affiliation>Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j">Nanomedicine (London, England)</title><idno type="eISSN">1748-6963</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Aim:</b> Nanotheranostics consisting of highly-fluorescent quantum dots coupled with gelatin/chondroitin layer-by-layer assembled nanocapsules were developed. <b>Materials & methods:</b> The hydrophobic drugs celecoxib (CXB) and rapamycin (RAP) were co-loaded into the oily core of nanocapsules (NCs) to enable synergistic growth inhibition of breast cancer cells. To overcome the nonspecific binding of actively targeted CS-NCs with normal cells, a matrix metalloproteinase (MMP-2)-degradable cationic gelatin layer was electrostatically deposited onto the surface of the negatively-charged CS-NCs. <b>Results:</b> The prepared nanocarriers displayed strong fluorescence which enabled tracing their internalization into cancer cells. An enhanced cytotoxicity of the NCs against breast cancer cells was demonstrated. <i>In vivo</i>, the nanoplatforms displayed superior antitumor efficacy as well as nonimmunogenic response. <b>Conclusion:</b> Therefore, these multifunctional nanoplatforms could be used as potential cancer theranostics.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">30073915</PMID><DateRevised><Year>2020</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1748-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>14</Issue><PubDate><Year>2018</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Nanomedicine (London, England)</Title><ISOAbbreviation>Nanomedicine (Lond)</ISOAbbreviation></Journal><ArticleTitle>Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging.</ArticleTitle><Pagination><MedlinePgn>1707-1730</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/nnm-2018-0028</ELocationID><Abstract><AbstractText><b>Aim:</b> Nanotheranostics consisting of highly-fluorescent quantum dots coupled with gelatin/chondroitin layer-by-layer assembled nanocapsules were developed. <b>Materials & methods:</b> The hydrophobic drugs celecoxib (CXB) and rapamycin (RAP) were co-loaded into the oily core of nanocapsules (NCs) to enable synergistic growth inhibition of breast cancer cells. To overcome the nonspecific binding of actively targeted CS-NCs with normal cells, a matrix metalloproteinase (MMP-2)-degradable cationic gelatin layer was electrostatically deposited onto the surface of the negatively-charged CS-NCs. <b>Results:</b> The prepared nanocarriers displayed strong fluorescence which enabled tracing their internalization into cancer cells. An enhanced cytotoxicity of the NCs against breast cancer cells was demonstrated. <i>In vivo</i>, the nanoplatforms displayed superior antitumor efficacy as well as nonimmunogenic response. <b>Conclusion:</b> Therefore, these multifunctional nanoplatforms could be used as potential cancer theranostics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>AbdElhamid</LastName><ForeName>Ahmed S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helmy</LastName><ForeName>Maged W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, El Bahira, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebrahim</LastName><ForeName>Shaker M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Materials Science, Institute of Graduate Studies & Research, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahey-El-Din</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology & Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zayed</LastName><ForeName>Dina G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zein El Dein</LastName><ForeName>Esmat A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Gizawy</LastName><ForeName>Sanaa A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elzoghby</LastName><ForeName>Ahmed O</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nanomedicine (Lond)</MedlineTA><NlmUniqueID>101278111</NlmUniqueID><ISSNLinking>1743-5889</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cancer nanotheranostics</Keyword><Keyword MajorTopicYN="N">celecoxib</Keyword><Keyword MajorTopicYN="N">rapamycin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30073915</ArticleId><ArticleId IdType="doi">10.2217/nnm-2018-0028</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Égypte</li><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="Égypte"><noRegion><name sortKey="Abdelhamid, Ahmed S" sort="Abdelhamid, Ahmed S" uniqKey="Abdelhamid A" first="Ahmed S" last="Abdelhamid">Ahmed S. Abdelhamid</name></noRegion><name sortKey="Abdelhamid, Ahmed S" sort="Abdelhamid, Ahmed S" uniqKey="Abdelhamid A" first="Ahmed S" last="Abdelhamid">Ahmed S. Abdelhamid</name><name sortKey="Bahey El Din, Mohammed" sort="Bahey El Din, Mohammed" uniqKey="Bahey El Din M" first="Mohammed" last="Bahey-El-Din">Mohammed Bahey-El-Din</name><name sortKey="Ebrahim, Shaker M" sort="Ebrahim, Shaker M" uniqKey="Ebrahim S" first="Shaker M" last="Ebrahim">Shaker M. Ebrahim</name><name sortKey="El Gizawy, Sanaa A" sort="El Gizawy, Sanaa A" uniqKey="El Gizawy S" first="Sanaa A" last="El-Gizawy">Sanaa A. El-Gizawy</name><name sortKey="Elzoghby, Ahmed O" sort="Elzoghby, Ahmed O" uniqKey="Elzoghby A" first="Ahmed O" last="Elzoghby">Ahmed O. Elzoghby</name><name sortKey="Elzoghby, Ahmed O" sort="Elzoghby, Ahmed O" uniqKey="Elzoghby A" first="Ahmed O" last="Elzoghby">Ahmed O. Elzoghby</name><name sortKey="Helmy, Maged W" sort="Helmy, Maged W" uniqKey="Helmy M" first="Maged W" last="Helmy">Maged W. Helmy</name><name sortKey="Helmy, Maged W" sort="Helmy, Maged W" uniqKey="Helmy M" first="Maged W" last="Helmy">Maged W. Helmy</name><name sortKey="Zayed, Dina G" sort="Zayed, Dina G" uniqKey="Zayed D" first="Dina G" last="Zayed">Dina G. Zayed</name><name sortKey="Zayed, Dina G" sort="Zayed, Dina G" uniqKey="Zayed D" first="Dina G" last="Zayed">Dina G. Zayed</name><name sortKey="Zein El Dein, Esmat A" sort="Zein El Dein, Esmat A" uniqKey="Zein El Dein E" first="Esmat A" last="Zein El Dein">Esmat A. Zein El Dein</name></country><country name="États-Unis"><region name="Massachusetts"><name sortKey="Elzoghby, Ahmed O" sort="Elzoghby, Ahmed O" uniqKey="Elzoghby A" first="Ahmed O" last="Elzoghby">Ahmed O. Elzoghby</name></region><name sortKey="Elzoghby, Ahmed O" sort="Elzoghby, Ahmed O" uniqKey="Elzoghby A" first="Ahmed O" last="Elzoghby">Ahmed O. Elzoghby</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000562 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000562 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30073915
|texte= Layer-by-layer gelatin/chondroitin quantum dots-based nanotheranostics: combined rapamycin/celecoxib delivery and cancer imaging.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30073915" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |